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Abstract
Sjo¨gren’s syndrome (SS) is a late-onset chronic autoimmune disease (AID) affecting the exocrine glands, mainly the salivary
and lachrymal. Genetic studies on twins with primary SS have not been performed, and only a few case reports describing
twins have been published. The prevalence of primary SS in siblings has been estimated to be 0.09% while the reported
general prevalence of the disease is approximately 0.1%. The observed aggregation of AIDs in families of patients with primary
SS is nevertheless supportive for a genetic component in its etiology. In the absence of chromosomal regions identified by
linkage studies, research has focused on candidate gene approaches (by biological plausibility) rather than on positional
approaches. Ancestral haplotype 8.1 as well as TNF, IL10 and SSA1 loci have been consistently associated with the disease
although they are not specific for SS. In this review, the genetic component of SS is discussed on the basis of three known
observations: (a) age at onset and sex-dependent presentation, (b) familial clustering of the disease, and (c) dissection of the
genetic component. Since there is no strong evidence for a specific genetic component in SS, a large international and
collaborative study would be suitable to assess the genetics of this disorder.
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What is Sjo¨gren’s syndrome?
The immune system does not normally respond to self
antigens, and consequently “normal” autoimmune
responses are low and do not lead to pathological
manifestations. This immunological tolerance was
postulated over 50 years ago, but its multifactorial
bases are still controversial (van Parijs et al. 1998).
Tolerance is generated at two levels. The “upper level”
of central tolerance develops primarily in fetal life, and
the “lower level” of peripheral tolerance develops
postnatally as a backup process. A faulty central
tolerance sets the stage for AID, while faulty
peripheral tolerance leads to overt manifestations.
AID is a clinical syndrome thought to be caused by the
loss of tolerance, and is characterized by activation of
T cells or B cells, or both, leading to pathology in the
absence of an ongoing infection or other discernible
cause (Davidson and Diamond 2001). Nevertheless, it
could be argued that a viral infection triggers the
autoimmune response by direct cell injury, molecular
mimicry, epitope spreading, bystander damage, and
“viral de´ja` vu” mechanisms (Anaya et al. 2005b;
Merkler et al. 2006). A key feature of immunology is
that autoimmune response is physiologic and occurs
in most persons, but pathologic autoimmunity (i.e.
AID) develops in around 5% of the population
(Cooper and Stroehla 2003). Thus, AID is the result
of genetic, hormonal, immunological and environ-
mental factors occurring simultaneously in an
individual (Anaya et al. 2005b).
Sjo¨gren’s syndrome (SS) is a chronic AID charac-
terized by a progressive lymphocytic and plasma cell
infiltration of the salivary and lachrymal glands,
accompanied by the production of autoantibodies
leading to xerostomia and keratoconjunctivitis sicca
(sicca-symptoms) (Anaya and Talal 1997). SS may
occur alone (primary) or in association with other AID
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(secondary), of which the most frequent are Hashi-
moto’s thyroiditis and rheumatoid arthritis (RA). The
spectrum of the disease may extend from an organ
specific autoimmune disorder (autoimmune exocrino-
pathy) to a systemic process involving the musculos-
keletal, pulmonary, gastrointestinal, hematological,
vascular, dermatological, renal and nervous systems.
Since the target tissue involved in the autoimmune
histopathologic lesions of SS is the epithelium, the
term “Autoimmune Epitheliitis” is currently used to
describe the disorder (Moutsopoulos 1994). In the
general population, the prevalence of primary SS
ranges between 0.5 and 2.7% and is most common in
the elderly (Anaya and Talal 1997; Thomas et al.
1998). This range may be attributed to the lack of
uniform diagnostic criteria. Primary SS may occur in
patients of all ages, but it mainly affects women
(female:male ratio of 9:1) during the fourth and fifth
decades of their lives (Anaya and Talal 1997). When SS
occurs in children or men, its clinical and serological
expressions are similar to the ones seen in adult women
(Anaya et al. 1995a,b). Comparative studies between
SS presentation in different ethnic populations
indicate that the disease is distributed homogeneously
in different parts of the world (Anaya and Talal 1997).
Although SS may also be associated with an increased
risk for B-cell lymphoma, the prevalence of such a
complication is less than 5% of the cases and is
reported more frequently in patients with primary SS
than in those with secondary SS (Anaya et al. 1995a).
A key event in the initial process leading to primary
SS seems to be increased epithelial cell apoptosis that
progresses to subsequent salivary gland lymphocytic
infiltration and autoantibody production (Hum-
phreys-Beher et al. 1999; Mitsias et al. 2006).
Immunohistologic analysis of lymphoid infiltrates in
salivary gland tissue from patients with primary SS
shows a high expression of human leukocyte antigen
(HLA)-DR on acinar and ductal epithelial cells,
suggesting that they may function as nonprofessional
antigen-presenting cells and interact with CD4þ T
cells (Fox et al. 1986). This interaction between
epithelial and T cells leads to further production of
cytokines and stimulation of B cell proliferation and
differentiation. In addition, other soluble factors (i.e.
nitric oxide) are released thus interfering with
glandular function (Anaya et al. 2001) (Figure 1).
Not all individuals with sicca-symptoms have SS
The diagnosis of SS is based on the combination of
symptoms (sicca-symptoms) and the presence of the
autoimmune characteristics defined above: activation
of T cells (i.e. positive salivary gland biopsy) or B cells
(i.e. presence of “specific” autoantibodies). However,
not all the individuals presenting sicca-symptoms have
SS. Those individuals resembling SS but lacking
the autoimmune criteria represent phenocopies
(Anaya et al. 2001). No single test of oral or ocular
involvement is sufficiently sensitive and specific to
form a standard diagnosis of SS. Only the simul-
taneous positivity of various tests with the presence of
subjective symptoms and serological abnormalities
(anti-Ro and anti-La antibodies) and the presence of a
score that is more than a “focus score” on the minor
salivary gland (MSG) biopsy allow sufficient accuracy
in the diagnosis of this disorder. Although no
worldwide consensus exists as to the diagnostic
criteria for SS, the Modified European classification
criteria for SS have become very popular (Vitali et al.
2002). The demonstration of focal lymphocytic
infiltrates on MSG biopsies has remained the gold
standard for the oral component of SS. A cluster of at
least 50 lymphocytes/4 mm2 is called a “focus score”
Figure 1. (A) Autoimmune response in primary SS. The epithelial cells (acinar and ductal) abnormally express HLA class II molecules and
are thought to be antigen presenting cells (APC) to CD4þ T cells. IFN-g induces HLA-class II, Fas and Bak expression, and participates in
the apoptosis of epithelial cells, leading to the appearance of cryptic (auto) antigens (La, Ro, a-fodrin, muscarinic receptors). IL-10 is highly
produced by CD4 T cells, and is responsible, together with IL-6, of B cell maturation and the synthesis of autoantibodies. IL-10 also
participates in the T cells recruitment. Other inflammatory mediators (nitric oxide–NO–hormones, metalloproteinases-MMP) and cytokines
are also released (i.e. IL-2, IL-1 and TNF-a), interfering with glandular function. (B) The three-stage-model of SS development. The disease
is favored by gender and polymorphic genes (1st) that make epithelial cell susceptible to apoptosis (2nd, probably under an infectious or toxic
insult), progressing then to salivary gland lymphocytic infiltration and subsequent production of autoantibodies and other soluble factors
(3rd), all of which interfere with glandular function leading to the main clinical signs and symptoms.
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(Daniels and Whitcher 1994). Multiple studies have
shown that a positive MSG biopsy is closely correlated
with keratoconjuntivitis sicca and anti-nuclear anti-
bodies directed against Ro and La antigens (Daniels
and Whitcher 1994).
Genetic evidence for SS
Although the pathological mechanisms of AIDs
remain poorly understood, a variety of studies have
demonstrated that genetic predisposition is a major
factor in disease susceptibility. In addition, given that
these diseases hold a diverse group of phenotypes with
overlapping features and that a tendency towards
familial aggregation exists, it is likely that common
underlying genes might be involved in AIDs (Criswell
et al. 2005). In this review, the genetic component of
SS is discussed on the basis of three observations: (a)
age at onset and sex-dependent presentation, (b)
familial clustering of the disease, and (c) dissection of
the genetic component.
Why is SS a female late-onset disease?
It has been postulated that environmental factors,
such as hormonal influence, UV light, environmental
exposures, and infectious agents play a role in the
development of AIDs such as SS (James et al. 2001;
Lockshin 2002), but these are still not completely
understood, and need further research. Consideration
of age as a factor contributing to the onset of AIDs at
midlife (age, 40–60) has been proposed. However,
detection bias could explain the apparently late-onset
of disease because the progression of SS is slow to
show signs and symptoms, making the age of onset
imperceptible. In addition, age-dependent alteration
of the biological functions may modify the develop-
ment of the disease (i.e. decreased apoptosis and
increased clonal activation of T cells, or decreased
ability to respond to antigenic or mitogenic stimu-
lation, etc.) (Hsu and Mountz 2003). Thus, the search
for epigenetic factors influencing the triggering of SS
is warranted.
The vast majority of patients with SS are female.
The genetic reason behind this highly sex-related
prevalence is poorly understood, although hormones
like prolactin have been incriminated in the patho-
physiology of the disease (Steinfeld et al. 2000; Taiym
et al. 2004; Ackerman 2006). X-chromosome
inactivation and the resultant tissue chimerism might
be involved in the female predisposition for AIDs such
as SS (Stewart 1999; Chitnis et al. 2000). Half the
somatic cells in females express antigens derived from
the paternal X and half from the maternal X. The
Burnet–Jerne theory of somatic generation of anti-
body diversity and forbidden clone elimination states
that lymphocytes under maturation in the thymus are
killed or suppressed if they present high or low affinity
towards a histocompatibility antigen. If this were to
hold for self antigens as well, females would escape
expressing one of their parental X chromosomes,
which would still be able to react to self. Then,
lymphocytes happening to pass the selection in the
thymus would meet only cells expressing one of the
parental X chromosomes. These would be more easily
predisposed to a deregulation of self-tolerance in
females than in males. This is known as the Kast
Conjecture (Kast 1977). Even though specific
responses to immunization do not appear to account
for the high sex ratio seen in AIDs (Lockshin 2002),
there is still a chance that chimerism among
immunological cells could represent a starting point
for perpetuating or acquiring an imbalance in self-
tolerance. Ultimately, X monosomy as a resource for
producing chromosome instability and also haploin-
sufficiency for X-linked genes have both been
suggested as playing critical roles in the predominance
of AIDs in females (Invernizzi et al. 2005). None of
the proposals presented have a complete experimen-
tally proven background and they are still part of a
discussion on sex-connotation.
Familial clustering of the disease
The powerful impact of genetic predisposition on
susceptibility is usually based on disease concordance
rates in monozygotic twins. Genetic contribution to
AIDs is supported by the rates of monozygotic
concordance, ranging from 15 to 60%, and by the
high aggregation coefficients or recurrent risk ratios
(lR) (Wandstrat and Wakeland 2001). However,
genetic studies in primary SS twins have not been
performed, and only a few case reports describing
twins have been published (Simila et al. 1978; Besana
et al. 1991; Ostuni et al. 1996; Houghton et al. 2005).
The estimated disease concordance rate for identical
twins would be on the lower-rank limit thus high-
lighting the importance of environmental factors in the
susceptibility of SS. The prevalence of primary SS in
siblings (KSS) has been estimated to be 0.09% (Anaya
et al. 2006b), while the reported general prevalence in
Caucasians has been estimated to be,0.1% (Bowman
et al. 2004). Therefore, genetic factors probably do not
play a major role in the development of SS.
The observed aggregation of AIDs in families of
patients with primary SS is nevertheless supportive for
a genetic component in the etiology of the disease.
Familial aggregation of autoimmune thyroid diseases
(AITD), systemic lupus erythematosus (SLE), RA,
diabetes mellitus type 1 (T1D), vitiligo, and all these
AIDs taken together as a trait has been reported in
families of primary SS patients (Block et al. 1975;
Reveille et al. 1983; 1984; Molta et al. 1989; Foster
et al. 1993a; Firooz et al. 1994; Ginn et al. 1998; Lin
et al. 1998; Broadley et al. 2000; Michel et al. 2001;
Prahalad et al. 2002; Sloka 2002; Alkhateeb et al. 2003;
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Priori et al. 2003; Tait et al. 2004; Houghton et al.
2005; Anaya et al. 2006a,b). Other familial approxi-
mations have shown a greater frequency of positive
Schimer’s test, abnormal antibodies to thyroglobulin
and elevated levels of gamma globulin on first-degree
relatives of SS patients, with a transitional frequency
among second-degree relatives (Bolstad et al. 2000a).
Dissection of the genetic component
Segregation analyses have not been performed in SS.
Current evidence indicates that as it occurs along with
other AIDs, SS cannot be clearly classified according
to a specific genetic Mendelian-like model (Bias et al.
1986; Anaya et al. 2005b). First, more than one gene
seems to be involved in the development and outcome
of the disease; therefore, the disease is polygenic.
Second, the genes responsible that have been involved
in its etiology do not represent rare variants, and are
polymorphic. Third, pleiotropic interactions and
possible epistasis may account for the development
of SS (Wandstrat and Wakeland 2001).
The efforts to unravel the genetic component of
SS have relied on association studies for disease
gene identification (Tables II and III) However, robust
analyses on candidate gene variants have not been
undertaken and only a few linkage studies have been
reported (Foster et al. 1993b). In the absence of
chromosomal regions identified by linkage studies,
research has focused on candidate gene approaches
(by biological plausibility) rather than on positional
approaches (Figure 1). As a result, several genes
encoding molecules involved in apoptosis (FAS,
FASLG), antigen processing and presentation (HLA-
DR, HLA-DQ, TAP1, TAP2), immune recognition
(MBL2, IGHG, IGK, ABCA7/HA-1), intercellular and
intracellular signaling (MMP9, CTLA4, PTPN22),
cytokine and chemokine transductional pathways
(IFNG, TGFB1, TNF, IL1B, IL1RN, IL13, IL4, IL6,
IL10 CCR5) and autoantigens (SSA1, CHRM3) have
been reasonably tested in association studies (Tables I
to III). However, little convincing replication and
functional evidence exists. Additionally, given the
patchy nature of linkage disequilibrium (LD) across
the human genome (Gabriel et al. 2002), several
associated polymorphisms would not have a causal role
but could be associated with the disease due to another
marker in its proximity. Furthermore, AID suscepti-
bility is more likely to depend on a combination of quite
subtle changes in the dynamic or expression of several
genes, many of which could be present in the healthy
population (Altshuler et al. 2000).
Major histocompatibility complex and HLA
associations
The major histocompatibility complex (MHC), the
most important region in the human genome withT
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Table II. Non-HLA genetic association studies.
Chromosomal
band Gene Variant Associated disease trait(s) P value OR 95% IC Case:control Population Reference
1p13.3 PTPN22 1858T (620W) Susceptibility 0.01 2.42 1.24–4.75 70:308 Colombian Gomez et al.
(2005)
1q23 FASLG IVSnt-124A/G,
IVS3nt169 T/-
NS 70:72 Norwegian Bolstad et al.
(2000b)
1q31–q32 IL10 Hap-1082G-
819C-592C
Susceptibility & early dis-
ease onset
NS 108 cases Australian Limaye et al.
(2000)
1q31–q32 IL10 Hap-1082-
819-592 GCC/ATA
Susceptibility ,0.05 1.9 0.95–3.62 62 cases Finnish Hulkkonen et al.
(2001a)
1q31–q32 IL10 Hap-1082G-
819C-592C
Susceptibility & early dis-
ease onset
0.006 &
0.034
5.3 & 5.5 63:150 Spanish Font et al.
(2002)
1q31–q32 IL10 IL-10.G9 Cutaneous vasculitis &
" IL-10 serum levels
0.04 & 0.02 5.3 & 5.5 1.2–2.4 & 1.1–2.2 39:15 Colombian Anaya et al.
(2002a)
1q31–q32 IL10 Hap-1082G-819C-592C Susceptibility 0.003 2.25 1.26–4.02 129:96 French Gottenberg et al.
(2004)
2p12 IGK Ig KM NS Australian Downie-Doyle
et al. (2002)
2p12 IGK Ig KM Anti-La, disease activity 0.016 65:66 Finnish Pertovaara et al.
(2004)
2q14 IL1B Hap-511C þ 3953T Susceptibility
(protective)
0.0006 0.43 0.25–0.74 69:392 Colombian Camargo et al.
(2004)
2q14 IL1B Hap-511CC-31TT
3877AA
Susceptibility ,0.05 101:105 Japanese Muraki et al.
(2004)
2q14.2 IL1RN ILRN*2 Susceptibility & disease
severity
,0.05 Perrier et al.
(1998)
2q14.2 IL1RN VNTR NS 39:76 Slovak Petrek et al.
(2002)
2q33 CTLA4 (AT)n in 30UTR NS 58:150 Tunisian Hadj Kacem
et al. (2001)
2q33 CTLA4 49G NS 58:150 Tunisian Hadj Kacem
et al. (2001)
3p21 CCR5 CCR5wt/CCR5D32
heterozygosity
Susceptibility
(protective)
0.043 0.349 0.109–0.983 39:76 Slovak Petrek et al.
(2002)
5q31 IL13 IL13 þ 2044A/G # serum IgA and b2m
# Purpura
0.030,
0.007
63:63 Finnish Pertovaara et al.
(2006)
5q31.1 IL4 IL4-590 T/C # VSG 0.010 63:63 Finnish Pertovaara et al.
(2006)
6p21.3 TAP1 TAP1 þ 333 þ 637 NS 74:76 Colombian (Anaya et al.
2005a)
6p21.3 TAP1 TAP1 þ 333 þ 637 NS 57:80 Colombian Anaya et al.
(2002b)
6p21.3 TAP1 Hap TNFa2
TAP*0101 TAP2*0101
Susceptibility 0.01 6.68 45:130 French Jean et al.
(1998)
6p21.3 TAP2 TAP2 þ 379 þ 565 þ 665 NS 74:76 Colombian Anaya et al.
(2005a)
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Table II – continued
Chromosomal
band
Gene Variant Associated disease trait(s) P value OR 95% IC Case:control Population Reference
6p21.3 TAP2 TAP2 þ 379 þ 565 þ 665 NS 57:80 Colombian Anaya et al.
(2002b)
6p21.3 TAP2 Hap TNFa2 TAP*0101
TAP2*0101
Susceptibility 0.01 French Jean et al.
(1998)
6p21.3 TAP2 *Bky2 (ATG! GTG; 577)
Met! Val
Anti-Ro antibody
production
0.05 108 cases Japanese Kumagai et al.
(1997)
6p21.3 TNF TNF-308A Susceptibility 2.9 1.90–4.57 67:430 Colombian Correa et al.
(2005a)
0.0001
6p21.3 TNF TNF-308A Susceptibility,
anti-SSB/La
0.00028 2.86 1.64–5.12 129:96 French Gottenberg et al.
(2004)
6p21.3 TNF TNFa2 NS 58:150 Tunisian Hadj Kacem
et al. (2001)
6p21.3 TNF TNFa10 NS Jean et al.
(1998)
6p21.3 TNF Hap TNFa2 TAP*0101
TAP2*0101
Susceptibility 0.01 Jean et al.
(1998)
6p21.3 TNF TNF-308 Clinical course &
immunological features
NS 65 patients Colombian Tobon et al.
(2005)
7p21 IL6 2174C/G " IL-6 plasma levels ,0.05 111:400 Finnish Hulkkonen et al.
(2001b)
7p21 IL6 2174C/G NS 129:96 French Gottenberg et al.
(2004)
10q11.2–q21 MBL2 CGT! TGT;codon 52 # histological grade and
# MBL
0.035 0.15 0.03–0.71 65:138 Finland Aittoniemi et al.
(1996)
10q11.2–q21 MBL2 GGC! GAC;codon 54 Susceptibility ,0.05 Japanese Tsutsumi et al.
(2001)
10q24.1 FAS 2671G, IVS2nt176C,
IVS5nt82C
Susceptibility 0.044,
0.030,
0.022
0.62,
1.71,
1.78
0.39–0.99, 1.05–
2.80, 1.079–2.90
70:72 Norwegian Bolstad et al.
(2000b)
11p15.5 SSA1 7216A/G Anti-SSA/Ro52
production
NS 111:97 Japanese Imanishi et al.
(2005)
11p15.5 SSA1 7649A/G, 9571C/T anti-Ro 52-kd–positive
patients
0.02,
0.00003
97:72 Norwegian Nakken et al.
(2001)
12q14 IFNG þ874A/T NS 129:96 French Gottenberg et al.
(2004)
14q32.33 IGHG GMz Milder form of pSS 0.004 65:66 Finnish Pertovaara et al.
(2004)
19p13.3 ABCA7 NS 94:545 Norway, Hungary
and Germany
Harangi et al.
(2005)
19p13.3 HA-1 500/504CA (168His) Susceptibility 0.003 94:545 Norway, Hungary
and Germany
Harangi et al.
(2005)
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respect to adaptive and innate immune regulation,
carries the major genetic influence on susceptibility to
AIDs due to its highly polymorphic genes (Horton
et al. 2004). The best identified genetic factors for
primary SS are the MHC class II genes, mainly HLA-
DR and HLA-DQ (Table I). HLA studies have two
ultimate purposes: identify genetic prediction markers
and provide new insights about the functional
mechanisms underlying antigen presentation and the
autoimmune response. As expected, patients with
diverse ethnic origins carry different HLA suscepti-
bility alleles (Mori et al. 2005), partly because
immune-response gene polymorphisms have been
shaped and naturally selected by population-specific
histories of infectious diseases (Pearce and Merriman
2006). Comparisons between associated haplotypes
have suggested critical cis- or trans-interaction of
MHC protein segments that may provide the crucial
conformation for peptide-binding and trigger specific
CD4þ T cell responses (Kang et al. 1993). The b1
chain of HLA-DR molecules contains polymorphic
residues which contribute five binding pockets: P1,
P4, P6, P7 and P9. These pockets influence the
peptide-binding specificity of different class II
molecules. The P4 pocket, conformed by the amino
acid residues (AAR) at positions b13, b70, b71 and
b74, is critical for antigenic presentation (Stern et al.
1994). The last three AAR are in contact with the
T cell receptor (TCR) and therefore, they are
important in determining T cell recognition of the
peptide–DR complex. The P4 pocket at the reported
primary SS-susceptibility alleles across populations:
DRB1*0301, *1101, *1104 and *0405 (Kang et al.
1993; Roitberg-Tambur et al. 1993), and DQB1
*0201 shares a common positively charged amino acid
sequence (Gregersen et al. 1987; Anaya et al. 2005a).
Having a positively charged P4 pocket implies that
those positive HLA molecules can only present a
neutral or negative peptide to T cells (Table I).
HLA-DQB1 susceptibility alleles also share a region
from AAR 59–69 located in the antigen-binding
groove (Kang et al. 1993). An aspartic acid (D) and an
isoleucine (I) at positions 66 and 67 are common AAR
among DQB1*0201, *0401, *0402 and *0601 (Kang
et al. 1993). Reveille et al. (1991) found that all
primary SS patients with anti-Ro antibodies have a
leucine (L) at position 26 of the HLA-DQB1 molecule
and a glutamine (Q) at position 34 of the
HLA-DQA1 molecule. Furthermore, a dose-depen-
dent contribution of DQa-34Q and DQb-26L, and
the DRB1*03-DQB1*02-DQA1*0501 haplotype
encompassing the shared DQb-DI motif, might
represent the strongest contributors to the formation
of an anti-Ro/anti-La response in primary SS patients
(Reveille et al. 1991).
Subsequent studies have found HLA class II alleles
to be associated with specific subsets of autoantibodies
rather than to the disease itself (Miyagawa et al. 1998;T
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Rischmueller et al. 1998; Gottenberg et al. 2003).
Although selection bias could account for those results,
HLA-DR2-DQA1*0102-DQB1*0602 (DR2-DQ1)
haplotype has been found to be strongly associated
with the presence of anti-Ro antibodies, whereas the
risk of anti-Ro antibody spreading to produce
precipitating anti-La antibodies might be higher in
primary SS patients carrying the DR3-DQA1*0501-
DQB1*02 (DR3-DQ2) haplotype (Rischmueller et al.
1998). Rischmueller et al. (1998) postulated that
separate HLA class II associations reflect T cell
recognition of unique epitopes derived from either or
both of the La/Ro ribonucleoproteins, which might
engender specific T helper responses thereby control
diversification of the autoantibody response. Gotten-
berg et al. (2003) provided data supporting the epitope
spreading hypothesis. They suggested that HLA-
DR15 could favor anti-Ro synthesis while HLA-DR3
could favor both anti-Ro and anti-La production. On
the other hand, the lack of association between HLA
markers and clinical disease features indicates that
HLA alleles do not predict clinical outcome (Gotten-
berg et al. 2003). However, both the heterogeneity of
the disease and insufficient sample size are certainly
obstacles to correct data analysis.
The haplotype HLA-DR3-DQ2 is part of the 8.1
ancestral haplotype (AH) (HLA-A1, C7, B8, C4AQ0,
C4B1, DR3 and DQ2) which has been consistently
associated with susceptibility to T1D, SLE, and other
immunologic disorders (Price et al. 1999). Carriers
of this 8.1 AH have an altered immune response
characterized by an increased B cell function and by
the synthesis of proinflammatory cytokines plus a
decreased T cell response (Price et al. 1999). These
immune abnormalities are also observed in patients
with primary SS (Anaya et al. 1999).
Non-HLA MHC genes
The extended MHC comprises an 8 Mb region at
6p21.3 and harbors approximately 200 genes, most of
them coding for immunoregulatory molecules (Hor-
ton et al. 2004). TAP1 and TAP2 gene products are
required for transporting and loading specific peptides
to the MHC molecules (Tan et al. 1982). Kumagai
et al. (1997) reported that TAP2*Bky2 (Val 577) allele
was associated with the production of anti-Ro
antibodies in Japanese. No association between TAP
alleles and primary SS was found in the Colombian
population (Anaya et al. 2002b). Studies considering
both TAP and HLA-DQB1 showed the existence of
LD between them, suggesting a primary association
caused by HLA-DQB1 alleles or perhaps by the
presence of another susceptibility gene located
between them in this chromosome region (Anaya
et al. 2002b). A mapping approach based on five
microsatellites spanning 5 cM intervals within the
MHC region predicted a new candidate region for
acquiring primary SS, located at the most centromeric
portion of the 6p21.31 chromosomal region (Anaya
et al. 2003). One of the most likely genes related to this
location appears to be BAK1 (Herberg et al. 1998),
which encodes a pro-apoptotic molecule belonging to
the Bcl-2 protein family.
Tumor necrosis factor-alfa (TNFa) is encoded by
the TNF gene, located within the class III region of the
MHC, and is highly polymorphic. Five microsatellites
and numerous single nucleotide polymorphisms
(SNP) in the TNF promoter, some of which may
regulate TNFa expression, have been described
(Louis et al. 1998). Gottenberg et al. (2004) found
an association between the 2308A (TNF2) allele and
SS patients positive for anti-La antibodies. We have
observed that this allele is a common susceptibility
factor in Colombians for primary SS, SLE and RA
(Correa et al. 2005a,b). Studies of TNF microsatellite
polymorphisms did not find any association in French
(Guggenbuhl et al. 2000) nor in Tunisian populations
(Hadj Kacem et al. 2001). Whether TNF association
with SS is primary or secondary to LD with HLA-
DRB1*03 and HLA-B8, is not clearly resolved yet
(Wilson et al. 1993).
Cytokine polymorphisms
Significantly higher serum cytokines and salivary
levels of messenger RNA (mRNA) have been found in
SS patients compared to control subjects for TNFa,
interleukin (IL)-6, IL-10, interferon-gamma (IFNg),
and lower salivary gland expression of transforming
growth factor beta1 (TGFb1) (Fox et al. 1994;
Koski et al. 1995; Ohyama et al. 1996). Although the
extent to which these factors may contribute to the
development and progression of primary SS remains
to be elucidated (Magnusson et al. 2001), their
polymorphic genes have been studied on the basis of
functional SNPs, most of them at their promoter, may
be related to protein expression (Table II).
IL-10 together with IL-6 plays a central role in the
maturation of plasma cells and in the activation
of immunoglobulin synthesis. In a murine model
resembling SS, transgenic expression of IL-10
induced apoptosis of glandular tissue and lymphocyte
infiltration consisting primarily of Fas-ligand (FasL)þ
CD4þ T cells, as well as in vitro up-regulation of FasL
expression on T cells (Saito et al. 1999). These
findings resemble those observed in primary SS
patients in whom increased production of IL-10 has
been demonstrated by peripheral blood T cells
(Villarreal et al. 1995), B cells, monocytes (Llorente
et al. 1994), and also at the inflammatory site in
MSG (Fox et al. 1994). The IL10 gene is highly
polymorphic. Two microsatellites and several SNPs
have been reported (Hulkkonen et al. 2001a).
Hulkkonen et al. (2001a) first reported an influence
of haplotype GCC at positions 21082, 2819 and
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2592 of IL10 gene on susceptibility to primary SS in
Finnish patients. Other studies have confirmed the
influence of IL10 locus on the disease (Limaye et al.
2000; Hulkkonen et al. 2001a; Font et al. 2002; Anaya
et al. 2002a; Gottenberg et al. 2004) (Table II).
The IL-1 family consists of IL-1a, IL-1b, two
receptors, and a specific IL-1 receptor antagonist (IL-
1Ra) which inhibits the activity of IL-1a and IL-1b
and modulates a variety of IL-1 related immune and
inflammatory responses. Increased IL-1Ra serum
levels in primary SS patients, as well as decreased
salivary levels, suggest an important role for the local
balance between IL-1 and IL-1Ra in the susceptibility
to and severity of disease (Arend 2002). IL-1Ra is
encoded by the IL1RN gene and a variable number of
tandem repeats polymorphism within intron 2 has
been shown to be a marker (IL1RN*2 allele) for severe
disease outcome (Perrier et al. 1998) (Table II).
Autoantigens as candidate genes
One of the central clues to the pathogenesis of SS
comes from the observation that the immune system
targets a restricted and highly specific group of
intracellular autoantigens which are ubiquitously
expressed in many tissues. The Anti-Ro/SSA anti-
bodies, commonly found in patients with SS and SLE,
recognize the Ro/SSA ribonucleoprotein. The cluster-
ing and marked concentration of these molecules in the
surface blebs of apoptotic cells, and their modification
by apoptosis-specific proteolytic cleavage and other
post-translational modifications, have focused atten-
tion on apoptosis as the potential initiating stimulus for
systemic autoimmunity in SS (Rosen and Casciola-
Rosen 2004). The Ro/SSA molecule is conformed by
either a single 60- or 52-kD immunoreactive protein
bound to 1 of 4 small RNA molecules (Itoh et al. 1991).
Ro52 is coded by the SSA1 gene located at 11p15.5
(Frank et al. 1993) and is thought to be a RING-finger-
type E3 ubiquitin ligase (Wada and Kamitani 2006).
The Ro60 gene (SSA2) maps to chromosome 1q31
(Frank and Mattei 1994) and it has been suggested that
it works as part of a quality control of discard pathway
for 5S ribosomal RNA (O’Brien and Wolin 1994). A
third molecule with the properties of a Ro/SSA
autoantigen is calreticulin, a 48-kD protein encoded
by the CALR gene at 19p13.3–p13.2.
Nakken et al. (2001) found three SNPs in the SSA1
gene associated with anti-Ro 52-kd autoantibodies in
Caucasian primary SS patients (Table III). One of
them þ7649A/G SNP is located at a putative TATA
box. Another þ9571C/T SNP, associated with both
anti-Ro 52-kD and anti-La antibodies, is located
upstream of an alternatively spliced site, generating a
shorter version of the protein (Ro52b). In contrast,
Imanishi et al. (2005) identified one in the first intron,
the þ7216A/G SNP, this variant was not associated
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with the disease risk but with the presence of anti-SS-
A/Ro52 antibody in patients with primary SS.
Transcript forms are known for La, another
ribonucleoprotein target expressed in MSG tissue of
patients with primary SS (Bachmann et al. 1996). A
frame-shift mutation in exon 7 of the SSB gene results
in a shorter version of La/SSB protein. The C-
terminal region of La/SSB contains one of the major
autoepitopes of this protein, and thus its modification
might alter its antigenicity (Bachmann et al. 1996).
Auto-antibodies directed against muscarinic M3
receptors may contribute to sicca symptoms and
autonomic dysfunction in patients with both primary
SS and secondary SS by inhibition of cholinergic
neurotransmission at postsynaptic M3 (Waterman et al.
2000; Goldblatt et al. 2002). The M3 gene (CHRM3) is
located at 1q43–44, and codes for a 590 amino acid
protein. The gene is intronless (Fenech et al. 2001).
Although the role of the anti-M3 response is not clear, it
has been suggested that these receptors might be
synthesized in response to the generation of cryptic
antigens that stimulate the activation of autoreactive T
lymphocytes, consequently provoking an abnormal
immune response and synthesis of antibodies (Rosen
and Casciola-Rosen 2004). Considering that M3 could
be a possible target autoantigen in primary SS, our
group performed a polymorphism screening in the
gene coding region for CHRM3 to test whether or not
the gene would be incriminated in the risk of
developing primary SS as has been observed in other
AIDs in which polymorphisms in the autoantigen
genes have been observed to be a risk factor for
these diseases (Forsythe et al. 2002; Tomer and Davies
2003). Using the PCR-single specific conformational
polymorphism technique and automated sequencing,
only two simultaneous deletions, with a low frequency
of 1.4% in the population under study were identified
at the nucleotide positions þ45 and þ53 (Figure 2).
Other studies have not been able to identify poly-
morphisms within the muscarinic coding or the
flanking region (Fenech et al. 2001). As a corollary,
the coding region of the CHRM3 gene receptor is
highly conserved and polymorphic variations within
this region are unlikely to contribute to muscarinic
receptor dysfunction in primary SS patients.
Conclusion and perspectives
Although the clinical presentation and course of SS
(i.e. phenotype) are similar among populations, the
disease is fairly heterogeneous. This might be
attributed to the effects of genotype (i.e. polymorphic
Figure 2. Coding region polymorphisms within the M3 muscarinic-receptor gene (CHMR3). (A) Chromosomal position and size of the
different obtained PCR fragments (F1–F4) used in the polymorphism screening of the CHMR3. The nucleotide numbering is shown for
reference as well as overlapped nucleotides within fragments. (B) Sequence variation screening within 2024 bp of the CHMR3 coding region.
Wells 3 and 4 are mutation samples, the other wells are wild type sequences from studied individuals. (C) Sequencing results showing a single
base pair deletion at positions þ45 and þ53. All sequences aligned perfectly with the published wild type Genbank sequence (NM_000740).
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genes) on phenotype under environmental or stochas-
tic effects. From a genetic point of view, SS seems to
be a complex disease, meaning that its inheritance
does not follow a Mendelian-like model, and thus it is
polygenic. However, the level of the genetic contri-
bution to the disease is unknown. The AH 8.1 as well
as IL10 and SSA1 loci have been consistently
associated with the disease although they are not
specific for SS. Aggregation of AIDs in families of
patients with primary SS suggests that autoimmunity
might be inherited as a trait rather than as a single
phenotype (Anaya et al. 2006a,b).
The vast majority of association studies performed
to date have been underpowered to detect the modest
genetic effects that are responsible for common
diseases (Plenge and Rioux 2006). Until recently,
most studies have examined only a few SNPs in any
candidate gene (which does not comprehensively test
genetic variation in the gene), and most studies have
examined only several tens of patients samples (which
is underpowered to detect a true-positive association
if the OR is modest (e.g. ,1.50)) (Tables I–III).
Human linkage studies of SS families, in addition to
analyses on maternal transmission, imprinting, and
X-chromosome inactivation will probably be an
important starting place of information in the future.
Identification of genes that generate susceptibility to
AIDs undoubtedly enhances our understanding of the
mechanisms that mediate these complex diseases and
will allow us to predict and prevent them as well as to
discover new therapeutic interventions. Thus, a large
international and collaborative study would be
suitable to find conclusive evidence for a specific
genetic component in SS.
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